Table 2. Effect of levothyroxine sodium treatment on anthropometric measures, thyroid hormone, and neudesin levels .

-	Patients before treatment	Patients after treatment	p
Length SDS	-0.03±0.72	-0.15±0.66	0.41
Weight SDS	-0.42±0.77	-0.01±0.51	0.76
BMI	14.23±1.49	15.76±1.32	<0.001
BMI SDS	-0.13±0.91	0.41±0.62	<0.001
Head circumference SDS	-0.43±0.80	-0.18±0.75	0.15
fT4 (pmol/L)	6.31±2.64	20.92±3.97	<0.001
TSH (mU/L)	280.99±297.37 170.23 (32.93, 1100)	4.89±16.07 1.52 (0.08, 24.12)	<0.001
Neudesin level* (ng/mL)	6.46±6.63 3.93 (0.31, 30.06)	12.85±18.74 6.15 (2.17, 70.05)	0.019

*The second blood sample obtained only in 26 of 32 children.

Non-normally distributed parameters were also presented as median (minimum, maximum).

fT4: free thyroxine, TSH: thyroid stimulating hormone, BMI: body mass index, SDS: standard deviation score